18F-OncoFAP is a small molecule radiotracer with ultra high affinity for Fibroblast Activation Protein (FAP). The product is suitable for the non-invasive detection of a variety of metastatic solid tumors, as FAP is overexpressed in more than 90% of epithelial cancers (e.g., malignant breast, colorectal, ovarian, lung, skin, prostate and pancreatic cancers, as well as in some soft tissue and bone sarcomas).
18F-OncoFAP consists of a small organic ligand targeting FAP labeled with 18F.
The program is partnered with Blue Earth Diagnostics (part of the Bracco Group) who is in charge of developing and commercializing 18F-OncoFAP.
ONGOING CLINICAL TRIALS
- OncoFAP-68Ga has recently entered in a first-in-man imaging study in patients with advanced solid cancers
- Additional studies with OncoFAP-68Ga (Imaging) and OncoFAP-177Lu (Therapy) are about to start
References
Selective tumor targeting enabled by picomolar fibroblast activation protein inhibitors isolated from a DNA-encoded affinity maturation library
Puglioli et al. (2023) Chem, 15(10):1431-1443
A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake
Galbiati et al. (2022) J Nucl Med, 63(12):1852-1858
An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications
Millul et al. (2021) PNAS, 118, 16, e2101852118
Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA
Backhaus et al. (2022) Eur J Nucl Med Mol Imaging, 49(6):1822-1832